ST. LOUIS, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Optime Care, a nationally recognized specialty pharmacy and an AscellaHealth Company, today announces an expanded arrangement with Rigel Pharmaceuticals, Inc, effective October 14, 2024, to include commercial distribution of TAVALISSE® (fostamatinib). TAVALISSE is an oral medicine that can help patients manage chronic immune thrombocytopenia (ITP) by protecting their platelets from destruction.
Lately, several companies have garnered attention for various reasons, and this article aims to delve into five of them, offering insights into their recent developments.
San Diego, CA -- (SBWIRE) -- 09/27/2021 -- Certain directors of Rigel Pharmaceuticals, Inc. are under investigation over possible breaches of fiduciary duties.
San Diego, CA -- (SBWIRE) -- 08/30/2021 -- An investigation was announced over potential securities laws violations by Rigel Pharmaceuticals, Inc. in connection with certain financial statements.
